Principal Product Manager, Real World Evidence Intelligence

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Product Manager, Real-World Evidence Intelligence to shape products and capabilities that help teams use real-world data to design better studies, evaluate feasibility, support regulatory and evidence strategies, communicate value, and monitor outcomes across the product lifecycle. This role will define and deliver RWE Intelligence capabilities through the right mix of internal products, RevCore platform capabilities, external data assets, SaaS platforms, vendor partnerships, and integrations. The mandate is to improve study design, protocol feasibility, enrollment assumptions, external comparator readiness, evidence generation speed, value communication, and post-approval monitoring. You will work on high-impact capabilities where data fitness, transparency, reproducibility, and speed directly affect clinical development decisions, regulatory confidence, access strategy, and patient impact. Own RWE Intelligence strategy and measurable outcomes Define the vision and roadmap for RWE products and capabilities across clinical development, regulatory, medical, HEOR, market access, safety, and post-approval use cases. Set success metrics tied to cohort discovery speed, question-to-answer time, data readiness, evidence generation cycle time, external comparator feasibility, value evidence readiness, and adoption. Prioritize capabilities that reduce manual evidence workflows, improve decision quality, support evidence strategy, and scale across programs, studies, and indications. Shape solutions around evidence questions and decisions Design product and platform solutions around key decision moments such as eligibility criteria evaluation, protocol feasibility, enrollment assumptions, RWD source selection, cohort definition, endpoint selection, external comparator feasibility, payer evidence planning, and post-approval monitoring. Conduct product discovery with evidence teams to identify high-value questions, workflow friction, reusable data needs, and scalable solution opportunities. Translate evidence workflows into clear requirements, user stories, evaluation criteria, and prioritized capabilities. Determine when to build, buy, partner, or integrate based on user value, data fitness, vendor maturity, compliance needs, scalability, interoperability, and maintainability. Establish trusted, reusable RWE data capabilities Partner with technical teams, vendors, and data providers to deliver priority RWE capabilities across RevCore and core evidence platforms. Clarify trusted sources and reusable data products across claims, EHR, registries, labs, genomics, mortality, SDOH, patient-reported outcomes, treatment patterns, utilization, cost, outcomes, survival, and safety data. Define evidence-grade standards for fitness-for-purpose, provenance, cohort reproducibility, analytic transparency, data quality, privacy, governance, and auditability. Ensure RWE capabilities turn real-world, clinical, economic, safety, regulatory, and vendor data into decision-grade insights, not just dashboards or one-off analyses. Enable self-service evidence intelligence, AI use cases, and adoption Enable self-service cohort discovery, evidence landscaping, outcomes explor